Search

Displaying results 3441 - 3450 of 7540 in total
  1. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15715
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  2. Drug

    Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15716
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  3. Drug

    Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB15756
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  4. Drug

    Influenza B virus B/Washington/02/2019 live (attenuated) antigen

    go.drugbank.com/drugs/DB15758
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  5. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630]. … Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].

  6. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    It is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.

    Synonyms: 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide
  7. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for

  8. Drug

    Stanozolol

    go.drugbank.com/drugs/DB06718
    ApprovedVet approved

    Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

  9. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer … Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  10. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    It is being developed by StressGen Biotechnologies Corp. … Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.